The Rising Tide of Stimulant Use: Challenges and Strategies for Treatment

The Rising Tide of Stimulant Use: Challenges and Strategies for Treatment enduring module is a recording from the live Regularly Scheduled Series dated May 6, 2021. If you claimed credit for this session at the live meeting, you should not claim credit for this module. 

Faculty

Needs Statement

Stimulant use, particularly methamphetamine use, has significant adverse effects on the brain and body.  As stimulant use has increased, medical consequences such as overdose and the need for hospitalization are rising. Stimulant use presents unique challenges also for addiction medicine providers treating opioid use disorder. Unlike treatment for opioid use disorder, there are no current FDA-approved medication treatments for stimulant use disorder making effective treatment challenging.  Research with currently available prescription medications to decrease stimulant craving and use and behavioral interventions may be helpful to consider in treatment planning for these complex cases. 

Target Audience

Physicians, Nurses, Nurse Practitioners, Physician Assistants, Pharmacists, Social Workers

 

Objectives

Upon completion of this activity, participants will be able to:

• Identify common stimulants, their pharmacologic action, and current trends in stimulant use.
• Explain the impact of co-occurring stimulant use and opioid use.
• Explain treatment options for stimulant use/use disorder including medications, psychosocial/behavioral interventions and treatment and harm reduction approaches.

Accreditation

In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

CME
This enduring material is designated for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

IPE Competencies

• Values/Ethics for Interprofessional Practice
• Roles/ Responsibilities
• Interprofessional Communication
• Teams and Teamwork

CPE
This knowledge-based activity will award 1.00 contact hour (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

CNE
The University of Kentucky, College of Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

This education activity is offered for a maximum of 1.0 ANCC contact hours.

The Kentucky Board of Nursing (KBN) approves The University of Kentucky, College of Nursing (UKCON) as a provider as well. ANCC and KBN approval of a continuing nursing education provider does not constitute endorsement of program content nor commercial sponsors. The University of Kentucky does not approve commercial products. This educational activity is offered for a maximum of 1.2 KBN contact hours. This program includes 0.3 KBN/ 0.25 ANCC hour of pharmacology credit.

Provider #: 3-0008-12-21-0204. In order to receive credit, participants complete CNE activity, complete the evaluation form. Certificates may be printed once the evaluation is completed. 

CME-HB1

ASWB ACE
As a Jointly Accredited Organization, UK HealthCare CECentral is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. UK HealthCare CECentral maintains responsibility for this course. Social workers completing this course receive 1.00 clinical continuing education credit.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months.  An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

None of the planners, faculty, and others in control of educational content for this educational activity have relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Acknowledgement

In collaboration with UK Substance Use Research Priority Area.